Integrin α10-Selected MSCs Treat Skin Defects
Summary
USPTO granted patent US12599633B2 to Xintela AB covering integrin α10-selected mesenchymal stem cell compositions for treating skin defects, with 20 claims. The patent protects cell populations and culture conditions that enhance viability and regenerative function in wound healing applications.
What changed
USPTO granted patent US12599633B2 to Xintela AB for integrin α10-selected mesenchymal stem cell compositions and methods for treating skin defects. The patent covers cell populations with enhanced viability, paracrine activity, and regenerative function for wound healing applications, including dosing parameters and administration routes for acute and chronic skin defects.
Competitors developing similar stem cell-based wound treatments should conduct freedom-to-operate analyses to assess potential infringement risks. The patent grants Xintela AB exclusive rights to the claimed compositions and methods, which may affect licensing strategies and competitive positioning in the regenerative medicine space.
What to do next
- Monitor for updates
- Review patent claims for freedom-to-operate analysis
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Mesenchymal stem cells for use in the treatment of skin defects
Grant US12599633B2 Kind: B2 Apr 14, 2026
Assignee
Xintela AB
Inventors
Evy Lundgren Åkerlund, Folke Sjöberg, Hooi Ching Lim, Ahmed Elserafy, Moustafa Elmasry
Abstract
The present invention relates to therapeutics and methods for treating skin defects using compositions comprising integrin al0-selected Mesenchymal Stem Cells (MSCs) Disclosed herein are integrin α10-selected MSC populations and culture conditions that enhance cell viability, paracrine activity, and regenerative function when administered to damaged skin tissue. The compositions promote wound healing, modulate inflammatory responses, and support re-epithelialization. Further disclosed herein are dosing parameters and administration routes suitable for improving healing outcomes in acute and chronic skin defects.
CPC Classifications
A61K 35/28 A61K 9/0014 A61P 17/02 A61L 2430/34
Filing Date
2022-05-20
Application No.
18560712
Claims
20
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.